Valuation: Karyopharm Therapeutics Inc.

Market Cap 44.65M 38.77M 36.14M 33.2M 62.8M 4.25B 63.49M 426M 167M 2.12B 168M 164M 7.03B P/E 2026 *
-0.45x
P/E 2027 * -0.72x
Enterprise Value 44.65M 38.77M 36.14M 33.2M 62.8M 4.25B 63.49M 426M 167M 2.12B 168M 164M 7.03B EV / Sales 2026 *
0.33x
EV / Sales 2027 * 0.26x
Free-Float
95.32%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Karyopharm Therapeutics Inc.

1 day-0.51%
1 week-72.36%
Current month+2.08%
1 month-79.58%
3 months-77.65%
6 months-70.08%
Current year-73.37%
1 week 1.8
Extreme 1.8
7.47
1 month 1.8
Extreme 1.8
10.86
Current year 1.8
Extreme 1.8
10.99
1 year 1.8
Extreme 1.8
10.99
3 years 1.8
Extreme 1.8
29.25
5 years 1.8
Extreme 1.8
220.95
10 years 1.8
Extreme 1.8
444.15
Manager TitleAgeSince
Chief Executive Officer 58 02/05/2021
Director of Finance/CFO 55 02/01/2025
Chief Tech/Sci/R&D Officer - 31/03/2023
Director TitleAgeSince
Director/Board Member 62 31/12/2012
Director/Board Member 61 31/03/2013
Director/Board Member 78 02/10/2013
Date Insider Type Main position Quantity % Market Cap.
28/07/26 Sell

Executive/Senior Manager

-189 0.0008%
14/05/26 Sell

Controller/Auditor

-53 0.0002%
17/02/26 Sell

Executive/Senior Manager

378 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%-72.36%-50.13%-92.78% 44.65M
+0.19%+14.01%+36.11%-1.40% 75.81B
+0.86%-9.15%+20.80%+181.80% 48.57B
+3.72%-4.47%-7.16%+18.96% 46.01B
+3.64%+10.69%-51.21%-51.75% 41.66B
+3.29%+4.15%+57.98%-22.15% 29.82B
+1.83%+1.46%+59.54%+85.60% 24.01B
+3.36%+2.44%+106.45%-48.17% 22.01B
+0.81%-2.97%-6.77%+164.33% 19.09B
+0.05%-5.99%+64.98%+113.20% 15.83B
Average +1.75%-7.19%+23.06%+34.76% 32.29B
Weighted average by Cap. +1.90%+2.06%+23.80%+39.33%

Financials

2026 *2027 *
Net sales 134M 116M 108M 99.46M 188M 12.72B 190M 1.28B 499M 6.36B 502M 491M 21.07B 175M 152M 141M 130M 246M 16.61B 248M 1.67B 652M 8.3B 656M 641M 27.51B
Net income -118M -102M -95.56M -87.78M -166M -11.23B -168M -1.13B -440M -5.61B -443M -434M -18.6B -105M -91.09M -84.93M -78.02M -148M -9.98B -149M -1B -391M -4.99B -394M -385M -16.53B
Net Debt - -
Logo Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Employees
228
Date Price Change Volume
04/08/26 US$1.960 -0.51% 3,767,523
03/08/26 US$1.970 +2.60% 4,514,606
31/07/26 US$1.920 -72.61% 22,398,319
30/07/26 US$7.010 +2.19% 4,540,851
29/07/26 US$6.860 -3.24% 436,891
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.970USD
Average target price
6.400USD
Spread / Average Target
+224.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KPTI Stock